Journal of Diabetes and Metabolic Disorders · Nov 18, 2026

Circulating LRG1 in heart failure: association with type 2 diabetes and antidiabetic therapy class

By Alrosan K, Odeh M, Alqudah A et al.

Background Heart failure (HF) and type 2 diabetes mellitus (T2DM) frequently coexist and share remodelling and inflammatory mechanisms. Although leucine-rich α-2 glycoprotein 1 (LRG1) has been identified as a biomarker associated with vascular remodelling, fibrosis, and inflammation, its role in HF patients with type 2 diabetes and its connection to antidiabetic treatments remains unclear. Methods 115 patients with HF were divided into three groups for this cross-sectional study: HF who had no previously documented diagnosis of diabetes mellitus and were not receiving antidiabetic medication at enrolment (n = 42), HF with T2DM treated with DPP-4 inhibitors (n = 35), and HF with T2DM treated with SGLT-2 inhibitors (n = 38). The groups’ clinical characteristics, metabolic parameters, and circulating LRG1 levels were compared. Results LRG1 levels differed significantly across the groups (p = 0.002), with the lowest levels observed in the SGLT-2 inhibitor group. A post hoc analysis revealed a significant difference between the SGLT-2 inhibitor group and group of no previously documented diagnosis of diabetes mellitus (p = 0.001). No significant correlations were observed between LRG1 and clinical or metabolic variables. Conclusion Circulating LRG1 levels in HF patients differed between study groups, with the lowest levels observed in the SGLT-2 inhibitor group. These findings suggest an association between treatment group and LRG1 levels, but the cross-sectional design precludes causal inference regarding the effects of antidiabetic medications on inflammatory and remodelling pathways.

doi.org/10.1007/s40200-026-02132-xBiomarkers

AgingResearch.News